Thesan Pharmaceuticals, a US-based dermatology-focused drugs developer, has received a “golden hello” to the pharma world in the form of $16m series A round co-led by European-based peers Novo Group and Novartis’ corporate venturing units. The investment will be used by Thesan (whose name is drawn from the eponymous goddess of the dawn and was…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
